Dr Benedikt Ley
Senior Research Fellow
PhD, University of Vienna, Austria, 2013; Master of Public Health, University of Liverpool, UK, 2011; Master of Science, University of Vienna, Austria, 2007
Benedikt Ley is a public health expert with a focus on diagnostics, Malaria and G6PD deficiency. He started his career in 2008 with the University of Vienna (Austria), based in Bangladesh working on infectious diseases in the Bangladesh / Myanmar border region.
He joined the International Vaccine Institute (Korea) based in Zanzibar and subsequently in Kenya focussing on typhoid fever. In 2012 Benedikt joined the Institute of Tropical Medicine, Antwerp (Belgium) where he worked on Salmonella spp. infections and in parallel completed his PhD in 2013 with the University of Vienna on the diagnosis of cholera and typhoid fever.
In 2014 Benedikt moved to Darwin, Australia, and joined the Menzies School of Health Research where he focuses on Malaria and G6PD deficiency. He also teaches in Menzies Postgraduate Public Health programs for Charles Darwin University and coordinates the Vivax Working Group of the Asia Pacific Malaria Elimination Network (APMEN).
- ACROSS Study: Populations at risk of malaria and drug induced haemolysis
- IMPROV Study: Short-course treatment regimen for radical cure of P. vivax malaria
- Optimising the radical cure of vivax malaria (OPRA)
- PRIMA clinical trial: Universal Radical Cure of P. vivax malaria
- SIRIN clinical trial: Radical cure of P. vivax malaria in Nepal
- Asia-Pacific Malaria Elimination Project (APMEN).
- Pfeffer, D.A., Ley, B., Howes, R.E., Adu, P., Alam, M.S., [...], Price, R.N._(Awaiting publication). Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis. PLoS Med.
- Ley, B., Winasti Satyagraha, A., Rahmat, H., von Fricken, M.E., Douglas, N.M., [...], Price, R.N. (2019). Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. PLoS Med, 16(12):e1002992.
- Taylor, W.R.J., Thriemer, K., von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., [...], Price, R.N. (2019). Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet, 394(10202), 929-938. doi: 10.1016/S0140-6736(19)31285-1.
- Alam, M.S., Kibria, M.G., Jahan, N., Thriemer, K., Hossain, M.S., [...], Ley, B. (2018). Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PLoS One, 13(11), 13:e0206331. doi: 10.1371/journal.pone.0206331.
- Commons, R.J., Simpson, J.A., Thriemer, K., Humphreys, G.S., Abreha, T., [...], Price, R.N. (2018). The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis, 18(9), 1025-1034. doi: 10.1016/S1473-3099(18)30348-7.
- Thriemer, K., Ley, B., Bobogare, A., Dysoley, L., Alam, M.S., [...] and Price, R.N. (2017). Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malaria Journal, 16:141.
- Ley, B., Thriemer, K., Jaswal, J., Poirot, E., Alam, M.S., [...] and Price, R.N. (2017). Barriers to routine G6PD testing prior to treatment with primaquine. Malaria Journal, 16:329.
- Ley, B., Bancone, G., von Seidlein, L., Thriemer, K., Richards, J.S., Domingo, G.J. and Price, R.N. (2017). Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malaria Journal, 16:361.
- Ley, B., Alam, M.S., O'Donnell, J.J., Hossain, M.S., Kibria, M.G., [...] and Richards, J.S. (2017). A Comparison of Three Quantitative Methods to Estimate G6PD Activity in the Chittagong Hill Tracts, Bangladesh. PLoS One, 12, e0169930.
- Ley, B., Alam, M.S., Thriemer, K., Hossain, M.S., Kibria, M.G., [...] and Khan, W.A. (2016). G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study. PLoS One, 11:e0154015.
Click here to view more Benedikt Ley publications
New research by Menzies’ malaria team is identifying innovative new ways to eliminate Plasmodium vivax (P. vivax) malaria by 2030.
Menzies investigators and international collaborators from ACROSS and other institutions have published a meta-analysis
Menzies investigators and international collaborators have published a meta-analysis and identified a point of care test for the diagnosis of G6PD deficiency with suitable reliability for routine use. Further feasibility studies are under way to assess its reliability under field conditions.
A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated.
MESA Correspondents bring you cutting-edge coverage from the 7th International Conference on Plasmodium vivax Research (ICPVR 2019).
The largest grant, of $257,767, goes to the Menzies School of Health Research for a project with collaborators in Bangladesh, Indonesia and the Netherlands.
Among the other projects funded are the Menzies School of Health Research partnering with Bangladesh, Indonesia and Nepal to develop malaria treatments.